Takeda Pharmaceutical Company Limited Stock Börse Stuttgart
Stocks
TKDA
US8740602052
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Börse Stuttgart
23:55:42 28/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 15.40 EUR | 0.00% |
|
0.00% | +17.56% |
| 08-29 | US FDA approves Takeda, Protagonist's drug for rare blood cancer | RE |
| 08-29 | Takeda's Mimrylo Gets FDA Approval to Treat Blood Cancer Condition | DJ |
| Market Cap | 9,261B 57.89B 49.89B 46.77B 42.7B 80.43B 5,533B 80.69B 555B 217B 2,793B 217B 213B | P/E 2027 * |
46.6x | P/E 2028 * | 29.8x |
|---|---|---|---|---|---|
| Enterprise Value | 13,163B 82.29B 70.91B 66.48B 60.69B 114B 7,864B 115B 789B 308B 3,970B 309B 302B | EV / Sales 2027 * |
2.81x | EV / Sales 2028 * | 2.72x |
| Free-Float |
99.26% | Yield 2027 * |
3.52% | Yield 2028 * | 3.59% |
Last Transcript : Takeda Pharmaceutical Company Limited
| Current month | +4.05% | ||
| 1 month | +0.65% | ||
| 3 months | +10.79% | ||
| 6 months | -2.53% | ||
| Current year | +17.56% |
| 1 week | 15.3 |  | 15.6 |
| 1 month | 14.1 | | 15.6 |
| Current year | 12.7 | | 16.2 |
| 1 year | 11.6 | | 16.2 |
| 3 years | 11.6 | | 16.2 |
| 5 years | 11.6 | | 16.2 |
| 10 years | 11.6 | | 18.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/01/2025 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 01/04/2024 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 47 | 01/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 60 | 01/06/2015 |
Steven Gillis
BRD | Director/Board Member | 73 | 01/01/2019 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 01/06/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | 0.00% | - | - | 57.89B | |
| -0.13% | -6.44% | +60.47% | +112.05% | 1,047B | |
| +0.85% | -0.81% | +52.77% | +63.15% | 646B | |
| -1.03% | -3.58% | +22.87% | +73.29% | 451B | |
| -1.46% | -4.50% | +37.43% | +38.41% | 355B | |
| -0.72% | -2.89% | +21.86% | +36.79% | 291B | |
| -1.19% | -2.21% | +1.35% | +12.29% | 252B | |
| -1.05% | -1.57% | +51.40% | +68.55% | 234B | |
| +0.08% | -1.78% | -17.64% | -54.29% | 203B | |
| -2.14% | -0.30% | +29.42% | +89.10% | 181B | |
| Average | -0.69% | -2.68% | +28.88% | +48.82% | 406.59B | |
| Weighted average by Cap. | -0.48% | -3.46% | +38.66% | +65.51% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,687B 29.3B 25.25B 23.67B 21.61B 40.71B 2,800B 40.84B 281B 110B 1,413B 110B 108B | 4,766B 29.79B 25.67B 24.07B 21.97B 41.39B 2,847B 41.53B 286B 111B 1,437B 112B 109B |
| Net income | 194B 1.21B 1.04B 979M 893M 1.68B 116B 1.69B 11.61B 4.53B 58.44B 4.55B 4.45B | 318B 1.98B 1.71B 1.6B 1.46B 2.76B 190B 2.77B 19.03B 7.42B 95.76B 7.45B 7.29B |
| Net Debt | 3,902B 24.39B 21.02B 19.71B 17.99B 33.89B 2,331B 34B 234B 91.23B 1,177B 91.58B 89.59B | 3,701B 23.14B 19.94B 18.69B 17.06B 32.14B 2,211B 32.25B 222B 86.53B 1,116B 86.86B 84.97B |
| Date | Price | Change |
|---|---|---|
| 28/08/26 | €15.40 | 0.00% |
| 27/08/26 | €15.40 | -0.65% |
| 26/08/26 | €15.50 | -0.64% |
| 25/08/26 | €15.60 | +0.65% |
| 24/08/26 | €15.50 | +0.65% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
- TKDA Stock
Select your edition
All financial news and data tailored to specific country editions
